Janux Therapeutics Inc (JANX) Stock Price, Quote & News

Company Profile

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 751 4493

Website: www.januxrx.com

Address:

10955 Vista Sorrento Parkway, Suite 200, San Diego, United States

Stackdoe1 Feb. 4 at 2:39 AM

$JANX $165 ✨️

0 · Reply

ilestz Feb. 3 at 11:07 PM

$JANX back down we go!

1 · Reply

RNASequencing Feb. 3 at 8:10 PM

$JANX @JoeDirty living rent free in Joe’s head while I made money on the Janux readout with time stamp below how many times do I have to dunk on you?

1 · Reply

Peterson28 Feb. 3 at 6:12 PM

$JANX wow. $7M dump this morning.

0 · Reply

MarketWarfare Feb. 3 at 3:34 PM

$JANX huge volume dump. CEO David Campbell has absolutely murdered this company and its shareholders. It is time for his immediate removal.

0 · Reply

JoeDirty Feb. 3 at 2:51 PM

$JANX Wiw , great call loser!!! LOLOLOL

1 · Reply

bigchouse Feb. 2 at 2:23 PM

$JANX The good, the bad and the ugly analysts' predictions.

1 · Reply

bc4 Jan. 30 at 7:20 PM

$JANX We all know, shorts actively work on small volume daily on this stock to hunt down stop losses. As long as you don't sell yours, they will end up to cover their own short. 1. This company values should be more than cash value. 2. Positive collaboration with BMY. These reasons alon give me a strong reason to hold till the next big pop up.

3 · Reply

ilestz Jan. 29 at 9:49 PM

$JANX any upcoming catalysts? no. so this will not be going up any time soon. they just started expansion cohorts so no updates on 008. 007 is gonna need a lot more work. No one cares about big pharma deals until they deliver smth. Management knows this is going nowhere which is why theyre not buying yet.

1 · Reply

Jangs Jan. 29 at 6:50 PM

$JANX this effin stock is going to be the death of me i swear.

0 · Reply

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

Jan 22, 2026, 2:02 PM EST - 12 days ago

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

BMY

Jan 22, 2026, 7:38 AM EST - 12 days ago

Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug

BMY

Jan 22, 2026, 7:00 AM EST - 12 days ago

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

Dec 23, 2025, 4:05 PM EST - 6 weeks ago

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

Dec 2, 2025, 10:58 AM EST - 2 months ago

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Dec 2, 2025, 10:50 AM EST - 2 months ago

Janux dives as gaps in prostate cancer study data worry investors

Dec 2, 2025, 8:41 AM EST - 2 months ago

Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

BWLP SIG

Dec 2, 2025, 8:30 AM EST - 2 months ago

Janux Therapeutics Stock Craters After ‘Positive' Cancer Drug Trial Data. Why It's Down 41%.

Dec 1, 2025, 11:13 PM EST - 2 months ago

Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript

Dec 1, 2025, 4:05 PM EST - 2 months ago

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Nov 24, 2025, 8:00 AM EST - 2 months ago

Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC

Nov 6, 2025, 4:01 PM EST - 3 months ago

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Aug 7, 2025, 4:01 PM EDT - 6 months ago

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 4:05 PM EDT - 6 months ago

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

Jul 31, 2025, 12:01 AM EDT - 6 months ago

Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash

Jul 24, 2025, 4:05 PM EDT - 6 months ago

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

Jul 17, 2025, 4:30 PM EDT - 7 months ago

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

May 15, 2025, 8:00 AM EDT - 9 months ago

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

May 8, 2025, 4:01 PM EDT - 9 months ago

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 5, 2025, 8:30 AM EDT - 9 months ago

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

Apr 5, 2025, 8:14 AM EDT - 10 months ago

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout

Feb 27, 2025, 4:01 PM EST - 1 year ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Jan 24, 2025, 4:01 PM EST - 1 year ago

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Jan 8, 2025, 9:00 AM EST - 1 year ago

Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data

Jan 2, 2025, 11:46 PM EST - 1 year ago

Best-Performing Stocks Of 2024

APP BYRN CADL DAVE INOD LUNR MSTR

Dec 6, 2024, 7:43 PM EST - 1 year ago

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Dec 4, 2024, 11:12 PM EST - 1 year ago

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Dec 3, 2024, 4:01 PM EST - 1 year ago

Janux Therapeutics Announces Proposed Public Offering

Dec 3, 2024, 10:49 AM EST - 1 year ago

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

Dec 3, 2024, 10:39 AM EST - 1 year ago

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results

Dec 2, 2024, 4:30 PM EST - 1 year ago

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Nov 25, 2024, 9:00 AM EST - 1 year ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Nov 19, 2024, 1:23 AM EST - 1 year ago

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

Nov 6, 2024, 4:01 PM EST - 1 year ago

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 22, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Announces Updates to Board of Directors

Jun 26, 2024, 8:32 AM EDT - 1 year ago

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy

May 7, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Apr 30, 2024, 12:06 AM EDT - 1 year ago

Janux Therapeutics (JANX) stock has gone parabolic: what next?

Apr 11, 2024, 9:00 AM EDT - 1 year ago

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 2, 2024, 2:10 AM EDT - 2 years ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT VKTX AMLX MCRB RAPT RVNC

Mar 20, 2024, 1:44 PM EDT - 2 years ago

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

Mar 8, 2024, 4:01 PM EST - 2 years ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 29, 2024, 1:22 AM EST - 2 years ago

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Feb 27, 2024, 5:15 PM EST - 2 years ago

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27, 2024, 5:00 PM EST - 2 years ago

Janux Therapeutics Announces Proposed Public Offering of Common Stock

Feb 27, 2024, 8:38 AM EST - 2 years ago

Janux Therapeutics surges as trial data for prostate cancer therapy shows promise

Feb 26, 2024, 4:05 PM EST - 2 years ago

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

Feb 20, 2024, 8:00 AM EST - 2 years ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008

Stackdoe1 Feb. 4 at 2:39 AM

$JANX $165 ✨️

0 · Reply

ilestz Feb. 3 at 11:07 PM

$JANX back down we go!

1 · Reply

RNASequencing Feb. 3 at 8:10 PM

$JANX @JoeDirty living rent free in Joe’s head while I made money on the Janux readout with time stamp below how many times do I have to dunk on you?

1 · Reply

Peterson28 Feb. 3 at 6:12 PM

$JANX wow. $7M dump this morning.

0 · Reply

MarketWarfare Feb. 3 at 3:34 PM

$JANX huge volume dump. CEO David Campbell has absolutely murdered this company and its shareholders. It is time for his immediate removal.

0 · Reply

JoeDirty Feb. 3 at 2:51 PM

$JANX Wiw , great call loser!!! LOLOLOL

1 · Reply

bigchouse Feb. 2 at 2:23 PM

$JANX The good, the bad and the ugly analysts' predictions.

1 · Reply

bc4 Jan. 30 at 7:20 PM

3 · Reply

ilestz Jan. 29 at 9:49 PM

1 · Reply

Jangs Jan. 29 at 6:50 PM

$JANX this effin stock is going to be the death of me i swear.

0 · Reply

MarketWarfare Jan. 29 at 3:03 PM

$JANX scumbag pos CEO needs to be forcefully removed from this company. He's an utter disaster. Clueless fk.

0 · Reply

Kevinb511 Jan. 29 at 11:34 AM

$JANX stuck here at $16 average. This thing is killing me

2 · Reply

ilestz Jan. 28 at 9:20 PM

$JANX its getting beyond ridiculous to even look at the price of this stock. this is criminal

0 · Reply

forprofit12 Jan. 28 at 9:04 PM

$JANX PoS lost all its gains from the meaningless deal signed with BMY. There is no short term or long term benefit to the deal.

0 · Reply

Dark_Horse_Investments Jan. 28 at 8:53 PM

$JANX how do we feel about the new Chief Medical Officer appointment? William Go, M.D., Ph.D for Zachariah McIver, D.O., Ph.D ... At least Chief Science officer is still on, Raimondo - though not sure how to feel about this... Any reactions...

0 · Reply

Suhair1977 Jan. 28 at 5:29 PM

$JANX Pure turd , short sellers are in control

1 · Reply

MarketWarfare Jan. 28 at 4:43 PM

$JANX shorts have no fear of the POS currently employed as the CEO of JANX. Why isn't this turd buying shares on the open market? Has he not killed the share price enough?

2 · Reply

BayerSlayer Jan. 28 at 4:30 PM

$JANX I knew I should’ve got out on last weeks pump & cut my losses! This stock is such a pos ugh

0 · Reply

bc4 Jan. 28 at 4:09 PM

$JANX same play every day. Short in AM and cover in PM to hunt down stop loss.

0 · Reply

ilestz Jan. 28 at 3:25 PM

$JANX any reason why we’ve decided to go in the complete wrong direction this morning?

1 · Reply

IllogicalMarket Jan. 28 at 2:18 AM

$JANX

0 · Reply

MarketWarfare Jan. 27 at 8:01 PM

$JANX like watching paint dry

1 · Reply

Market Cap	824.63M
Revenue (ttm)	10.59M
Net Income (ttm)	-68.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-651.46%
Debt to Equity Ratio	0.00

Volume	2,810,200
Avg Vol	2,338,348
Day's Range	N/A - N/A
Shares Out	60.15M
Stochastic %K	21%
Beta	2.88
Analysts	Strong Sell
Price Target	$58.65